Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently

As expectations of the future tamper down, Novo Nordisk ( NVO ) is currently adequately priced in the near term, but likely underpriced compared to its mid- to long-term potential. At a 25% revenue CAGR over the next five years, theI am an individual investor and student of value investing. I specialize in strategic analysis of situations, trying to assess stocks with common sense and simple valuation models to add robustness to my thinking. I am sector agnostic and my primary focus in stock picking is on m ...